These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27277528)

  • 1. Cancer therapy-related complications in the bowel and mesentery: an imaging perspective.
    Gray EJ; Darvishzadeh A; Sharma A; Ganeshan D; Faria SC; Lall C
    Abdom Radiol (NY); 2016 Oct; 41(10):2031-47. PubMed ID: 27277528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management.
    Shinagare AB; Howard SA; Krajewski KM; Zukotynski KA; Jagannathan JP; Ramaiya NH
    AJR Am J Roentgenol; 2012 Dec; 199(6):1259-65. PubMed ID: 23169717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients.
    Thornton E; Howard SA; Jagannathan J; Krajewski KM; Shinagare AB; O'Regan K; Cleary JM; Ramaiya NH
    Br J Radiol; 2012 Oct; 85(1018):1420-6. PubMed ID: 22674709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment and management of gastrointestinal toxicities and lab abnormalities related to targeted therapy.
    Fischer-Cartlidge EA
    Semin Oncol Nurs; 2014 Aug; 30(3):183-9. PubMed ID: 25085030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events of targeted therapies.
    Klastersky JA
    Curr Opin Oncol; 2014 Jul; 26(4):395-402. PubMed ID: 24825019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.
    Kheir WJ; Sniegowski MC; El-Sawy T; Li A; Esmaeli B
    Surv Ophthalmol; 2014; 59(5):493-502. PubMed ID: 25130892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT of the small bowel and mesentery.
    Merine D; Fishman EK; Jones B
    Radiol Clin North Am; 1989 Jul; 27(4):707-15. PubMed ID: 2657849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abdominal and pelvic complications of nonoperative oncologic therapy.
    Viswanathan C; Truong MT; Sagebiel TL; Bronstein Y; Vikram R; Patnana M; Silverman PM; Bhosale PR
    Radiographics; 2014; 34(4):941-61. PubMed ID: 25019433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of complications of oncological therapy in the gastrointestinal system.
    Viswanathan C; Bhosale P; Ganeshan DM; Truong MT; Silverman P; Balachandran A
    Cancer Imaging; 2012 May; 12(1):163-72. PubMed ID: 22571819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity.
    Torrisi JM; Schwartz LH; Gollub MJ; Ginsberg MS; Bosl GJ; Hricak H
    Radiology; 2011 Jan; 258(1):41-56. PubMed ID: 21183492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.
    Cramer P; Bresalier RS
    Curr Gastroenterol Rep; 2017 Jan; 19(1):3. PubMed ID: 28124291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Magnetic Resonance Enterography in the Evaluation of Non-Crohn׳s Pathologies.
    Griffin N; Westerland O
    Semin Ultrasound CT MR; 2016 Aug; 37(4):292-300. PubMed ID: 27342893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.
    Abramson RG; Abramson VG; Chan E; Horn L; Keedy VL; Pao W; Sosman JA
    AJR Am J Roentgenol; 2013 Mar; 200(3):475-83. PubMed ID: 23436834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical involvement of mesenteric and antimesenteric borders of small bowel loops. II. Radiologic interpretation of pathologic alterations.
    Meyers MA
    Gastrointest Radiol; 1976; 1(1):49-58. PubMed ID: 829905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unusual bowel complication during molecularly-targeted therapy.
    Adachi K; Okamoto S
    Dig Liver Dis; 2015 Nov; 47(11):e20. PubMed ID: 26210306
    [No Abstract]   [Full Text] [Related]  

  • 16. Cutaneous Reactions to Targeted Therapy.
    Lee JJ; Kroshinsky D; Hoang MP
    Am J Dermatopathol; 2017 Feb; 39(2):67-82. PubMed ID: 28134724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases.
    Assoun S; Lemiale V; Azoulay E
    Intensive Care Med; 2019 Jul; 45(7):988-997. PubMed ID: 31143997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onconephrology: What Should the Internist Know About Targeted Therapy in Solid Tumors?
    El Rassy E; El Karak F; Rizkallah J; Chelala D
    Iran J Kidney Dis; 2016 Jul; 10(4):169-75. PubMed ID: 27514761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies.
    Chang ST; Menias CO; Lubner MG; Mellnick VM; Hara AK; Desser TS
    Radiographics; 2017; 37(5):1461-1482. PubMed ID: 28753381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Management of adverse effects of targeted therapy toxicities in oncology].
    Coquan E; Henri P; de Raucourt S; Lireux B; Lamy E; Delcambre C; Sevin E; Dutriaux C; Bouhier-Leporrier K; Gervais R; Joly F
    Rev Prat; 2012 Jan; 62(1):17-25. PubMed ID: 22335060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.